Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digirad gears up for nSPEED trial:

This article was originally published in Clinica

Executive Summary

Gamma camera manufacturer Digirad is gearing up to start multicentre trials of its nSPEED technology - an advanced 3D SPECT image reconstruction technique. During the trial, the company hopes to show that nSPEED can cut acquisition time for cardiac SPECT in half, while maintaining clinical results equivalent to or better than 2D reconstruction techniques. The firm said it is currently "striving" to obtain acceptance from the American Society of Nuclear Cardiology and other societies in order to meet accreditation requirements for the product. nSPEED models depth-dependent point response function in an iterative reconstruction algorithm (OSEM), enabling depth-dependent resolution recovery and improving chamber contrast in SPECT images.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel